June 2, 2026 |
Across sessions, panels, and conversations on the ground in Denver, there was a noticeable shift in both mindset and momentum. Many of the themes discussed in previous years are now being actively implemented, with teams moving beyond theory and into execution.

Here are five key takeaways shaping the future of Medical Affairs.
1. Medical Affairs is stepping into a strategic leadership role
Medical Affairs is no longer operating at the margins of strategy. It is increasingly being brought earlier into the development process, co-leading product launches, in some situations functionally leading product launch, and influencing enterprise decision-making.
As Gemma Pfister (Senior Consulting Executive, Inizio Ignite) and Eric Wood (Head of Commercial, Transformation, Inizio Ignite) observed, teams are now “required to translate complex science into enterprise value,” reflecting a fundamental shift in expectations.
There is also a growing emphasis on engaging at a more senior level. Varun Renjen (Partner, Inizio Ignite) highlighted the importance of Medical Affairs leaders being able to “speak the pipeline, the top line and the bottom line,” reinforcing the need for commercial fluency alongside scientific expertise.
This evolution marks a turning point. Medical Affairs is not just supporting strategy, it is helping define it.
2. The shift from activity to impact is accelerating
A consistent theme throughout MAPS was the need to move beyond activity-based metrics and demonstrate real, measurable impact.
Jo Ann Saitta (Head of Data & AI, Inizio Ignite), pointed to the growing focus on “where they are moving the needle on patient impact,” with teams increasingly leveraging real-world data to demonstrate changing behaviors and value.
Importantly, this is not about proving value for the first time. As Eric Wood reflected, “medical has already reached the milestone of proving effectiveness.” The challenge now is to communicate that value more clearly and consistently across the organization.
Dean McAlister (Executive Vice President, Biotech Enterprise Solutions, Inizio Biotech) captured this shift powerfully, highlighting the importance of bringing data to life through storytelling: “we move it from hands and feet to the hearts and minds of the people involved.”
The implication is clear. Demonstrating impact is no longer optional. It is a core capability for Medical Affairs teams.
Read the full blog here.
This content was provided by Inizio
Latest Content from Inizio
At Fierce Pharma Week, Inizio revealed how the fusion of human expertise and purposeful AI is reshaping pharma communications and driving real-world impact—discover how this human-centered innovation is defining the...
Inizio is leading the way in Intelligent Commercialization™ by uniting proprietary AI-powered platforms, deep scientific expertise, and proven governance to unlock measurable, lasting value at every stage of commercialization.
We’re attending Obesity Week 2025, the world’s leading event dedicated to obesity research and care, to showcase how our integrated expertise is advancing progress in obesity and cardiometabolic health.
Inizio has appointed Mary-Kate McGarry as Chief Strategy & Innovation Officer and Gavin McShera as Chief Information Officer, strengthening its executive leadership to drive innovation, digital transformation, and Intelligent Commercialization™...
Inizio has been named a finalist in six categories at the 2025 PM360 Trailblazer Awards, recognizing its teams’ excellence in AI, data analytics, education, patient engagement, and industry partnership across...
Inizio experts contribute to Forbes’ Voices of Oncology, highlighting our commitment to driving innovation in cancer care through advanced data analytics, cross-sector collaboration, and real-world impact for patients.
Inizio have appointed Ryan Quigley as Chief Executive Officer, effective 9 September 2025. Paul Taaffe will remain closely involved with the company as an Advisor and board member going forward. ...
Simon Davenport, Global Head of Environments, Emota, an Inizio Engage company At this year’s ASCO® congress, the spotlight wasn’t just on science – it was on how the industry engages. Supporting over 30...
Nick Bellomo, Director of Technology and Engagement, Inizio Medical ASCO® 2025 wasn’t just about oncology breakthroughs - it was also a showcase for how technology is redefining congress engagement. Supporting...
Patty Zipfel, PhD, SVP, Scientific Strategy, Inizio Evoke. This year’s ASCO® meeting spotlighted a bold shift in oncology: the possibility of curing metastatic disease. A new trial design in metastatic...
